Scientific Program

Time Room A [English]
08:20-08:30 Opening and Course Introduction
08:30-09:50 New Concepts in VHD in 2026 II
08:30-08:43 Lifetime Management in SHD: Integrating Risk Control and Strategic Intervention Timing
08:43-08:56 CCTA for Valve Intervention: New Standard or Selective Alternative?
08:56-09:09 Structural Valve Deterioration: From Mechanisms to Clinical Impact
09:09-09:22 Antithrombotic Management after TAVI
09:22-09:35 When "Moderate" Is Not Benign: Rethinking Risk in Multivalvular VHD
09:35-09:50 Panel Discussion
09:50-10:10 Coffee Break
10:10-11:00 Plenary Lectures
10:10-10:30 CT at the Center of Structural Heart Intervention: From Patient Selection to Lifetime Management                                                                   
10:30-10:50 TAVI Today and Tomorrow: International Trends and Future Direction
10:50-11:00 Discussion (10 min)
11:00-12:20 Aortic Valve Disease: Current Strategies for Management and Unresolved Questions
11:00-11:13 Imaging-Guided Decision Making in Aortic Stenosis and TAVI - What May Impact the Outcome?
11:13-11:26 Structural Heart Echocardiography in Complex TAVR Procedures (Low Coronary Height and AR)
11:26-11:39 Specific Anatomical Features in Patients in Asia - Leaflet Modifications for TAV-in-SAV
11:39-11:52 Totally Endoscopic Aortic Valve Replacement with 3D Visualization: UMC's Experience
11:52-12:05 Management of AR: Current Strategies and Unresolved Questions
12:05-12:20 Panel Discussion
12:20-13:30 Luncheon Session
12:20-12:40 Topic 1
12:40-13:00 Topic 2
13:30-14:40 HEART TEAM AT WORK, Learn from Case: Tricuspid Regurgitation
13:30-13:40 Patient Presentation and Imaging Analysis
13:40-13:45 Discussion and Audience Interaction
13:45-13:57 Anatomy and Mechanisms of Tricuspid Regurgitation: Imager's Point of View
13:57-14:09 Tricuspid Valve Repair: Surgery or Transcatheter?: Surgeon's Point of View
14:09-14:21 When and Where Does T-TEER and TTVR Fit in and More: Interventionist's Point of View
14:21-14:31 Heart Team Discussion and Audience Interaction
14:31-14:40 How Did Our Case End
14:40-15:00 Coffee Break
15:00-16:20 Essentials in Management of Tricuspid Regurgitation
15:00-15:13 TR Assessment: Limitations of Current Metrics and Emerging Solutions
15:13-15:26 Patient Selection for Transcatheter Therapies for TR: Who Gets What
15:26-15:39 Tricuspid TEER Procedure: Techniques, Tips, and Pitfalls
15:39-15:52 Tricuspid Valve Imaging for T-TEER: Optimal Imaging Guidance Using 3D TEE & ICE
15:52-16:05 Challenging Candidates for T-TEER and New Solutions
16:05-16:20 Panel Discussion
16:20-17:40 2026 SHD in Asia: New Innovations in SHD Management
16:20-16:33 Advanced Valve Function Analysis Using 3D Echocardiography: State of the Art and What Lies Ahead?
16:33-16:46 Minimal Invasive & Robotic Surgery in Interventional Era
16:46-16:59 Transcatheter Electrosurgery and Leaflet Modification of the Valve
16:59-17:12 Echo-Guided Interventions in Congenital Heart Disease
17:12-17:25 Paravalvular Leak Closure: Indications, Techniques, and Outcomes
17:25-17:40 Panel Discussion
17:40 Closing Remark
17:45 Lucky Draw
Time Room B [Korean]
08:20-08:30 Opening and Course Introduction
08:30-09:50 [B6] The Tricuspid Valve in 360°: Measure, Guide, Judge
08:30-08:45 Basic of Tricuspid Regurgitation: Pathophysiology, Etiology, and Severity
08:45-09:00 Multimodality Imaging for Tricuspid Regurgitation
09:00-09:15 Functional TR: When to Intervene, When to Observe?
09:15-09:30 Did It Deliver? RV Function and TR Evaluation After Intervention
09:30-09:50 Panel Discussion
09:50-10:10 Coffee Break
10:10-11:20 [B7] Basic of Basic in T-TEER
10:10-10:23 Preprocedural Assessment and Patient Selection
10:23-10:36 Basic of Intraprocedural TEE Imaging for T-TEER: The Must-Have Views You Cannot Miss
10:36-10:49 Intraprocedural ICE Imaging: Essential Views Every T-TEER Needs
10:49-11:02 Basic of Tricuspid TEER: Step-by-Step
11:02-11:20 Panel Discussion
11:20-12:20 [B8] Nightmares in Structural Intervention
11:20-11:32 My Unforgettable AV Intervention: The Case I Still Think About
11:32-11:44 My Unforgettable Congenital Heart Disease Procedure: The Case I Still Think About
11:44-11:56 My Unforgettable MV Intervention: The Case I Still Think About
11:56-12:08 My Unforgettable Tricuspid Intervention: The Case I Still Think About
12:08-12:20 Panel Discussion
12:20-13:30 Luncheon Session (Sponsored Session)
12:20-12:40 Topic 1
12:40-13:00 Topic 2
13:30-14:30 [B9] The Aortic Stenosis in 360°: Measure, Guide, Judge
13:30-13:42 Echo Cardiographic Measure, Interpret, and Decide: Are We Getting It Right?
13:42-13:54 Reading TAVI CT from A to Z: What to Look For, What to Decide
13:54-14:06 When the Gradient Says No, but the Valve Says Yes: Low-Gradient Severe AS
14:06-14:18 Follow-up of Prosthetic Aortic Valve: What to Look For, What to Do
14:18-14:30 Panel Discussion
14:30-15:00 Coffee Break
15:00-16:00 [B10] Aortic Regurgitation in 360°: Measure, Guide, Judge
15:00-15:12 Echo Cardiographic Measure, Interpret, Decide: When the Numbers Lie
15:12-15:24 Multimodal Imaging for Aortic Regurgitation: Rvol Criteria of AR by CMR
15:24-15:36 Up-to-Date Interventional Treatment of AR
15:36-15:48 Up-to-Date Surgical Treatment of AR
15:48-16:00 Panel Discussion
16:00-17:20 [B11] Plugging the Gap: Anatomy-Driven Device Selection
16:00-16:15 LAAO Device Selection: Matching the Device to the Appendage
16:15-16:30 ASD Closure: From Rim Deficiency to Device Choice
16:30-16:45 Closing the PFO: Long Tunnel, Atrial Septal Aneurysm - Does the Device Change?
16:45-17:00 Closing the VSD: Who Needs It, and How I Do It
17:00-17:20 Panel Discussion
17:40 Closing Remark
17:45 Lucky Draw
Time Room C [Korean]
08:20-08:30 Opening and Course Introduction
08:30-09:50 [C6] Diagnosing Cardiomyopathy: A Toolbox for Genetic and Acquired Disease
08:30-08:45 Diagnosing Cardiac Sarcoidosis: Recognizing the Great Mimicker
08:45-09:00 Management of Cardiac Sarcoidosis: Treatment and Follow-up
09:00-09:15 Nuclear Imaging of Myocardial Inflammation
09:15-09:30 Arrhythmogenic Cardiomyopathy: Imaging and Genetic Red Flags
09:30-09:50 Panel Discussion
09:50-10:10 Coffee Break
10:10-11:50 [C7] Fabry Disease Across Asian Countries: A Multinational Perspective
10:10-10:30 Fabry Disease in Japan: From the GLA Variant Spectrum
10:30-10:50 Fabry Disease in Korea: Registry and Real-World Data
10:50-11:10 Fabry Disease in Taiwan: Insights from National Cohort
11:10-11:30 Fabry Disease in Vietnam: Epidemiology and Care
11:30-11:50 Panel Discussion
12:20-13:30 [C8] Luncheon Session (사노피)
12:20-12:40 Topic 1
12:40-13:00 Topic 2
13:30-15:10 [C9] Fabry Disease: Basic Research Presentation
13:30-13:55 Hippocampal Globotriaosylceramide (Gb3) Accumulation
13:55-14:20 Intestinal Organoid of Fabry Disease
14:20-14:45 AAV9/hGLA Gene Therapy in a Fabry Disease Model
14:45-15:10 Panel Discussion
15:10-15:30 Coffee Break
15:30-17:10 [C10] Fabry Disease: Clinical Research Presentation
15:30-15:50 Perifoveal Microvascular Alterations in Fabry Disease
15:50-16:10 TBD
16:10-16:30 Characterizing Audiological Profiles in Fabry Disease
16:30-16:50  Newborn Screening for Fabry Disease in Japan
16:50-17:10  Panel Discussion
17:40 Closing Remark
Education and Research Center for Rare and Structural heart disease (ERCRS)
1F, Baek-song Blg., Hakdong-ro 11-gil 56, Gangnam-gu, Seoul, Korea Zip: 06039
E-mail: echo360@echo360.co.kr | Office: +82-2-6002-1394 / 1392 | Fax: +82-2-583-0980
Business registration number: 507-82-76327 | Representative: Geu-Ru Hong